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Abstract 
Glioblastoma (GBM) is a universally fatal brain cancer, for which novel therapies targeting specific underlying 
oncogenic events are urgently needed. While the WNT pathway has been shown to be frequently activated in 
GBM, constituting a potential therapeutic target, the relevance of WNT6, an activator of this pathway, remains 
unknown.  
Methods: WNT6 protein and mRNA levels were evaluated in GBM. WNT6 levels were silenced or 
overexpressed in GBM cells to assess functional effects in vitro and in vivo. Phospho-kinase arrays and TCF/LEF 
reporter assays were used to identify WNT6-signaling pathways, and significant associations with stem cell 
features and cancer-related pathways were validated in patients. Survival analyses were performed with Cox 
regression and Log-rank tests. Meta-analyses were used to calculate the estimated pooled effect. 
Results: We show that WNT6 is significantly overexpressed in GBMs, as compared to lower-grade gliomas 
and normal brain, at mRNA and protein levels. Functionally, WNT6 increases typical oncogenic activities in 
GBM cells, including viability, proliferation, glioma stem cell capacity, invasion, migration, and resistance to 
temozolomide chemotherapy. Concordantly, in in vivo orthotopic GBM mice models, using both 
overexpressing and silencing models, WNT6 expression was associated with shorter overall survival, and 
increased features of tumor aggressiveness. Mechanistically, WNT6 contributes to activate typical oncogenic 
pathways, including Src and STAT, which intertwined with the WNT pathway may be critical effectors of 
WNT6-associated aggressiveness in GBM. Clinically, we establish WNT6 as an independent prognostic 
biomarker of shorter survival in GBM patients from several independent cohorts.  
Conclusion: Our findings establish WNT6 as a novel oncogene in GBM, opening opportunities to develop 
more rational therapies to treat this highly aggressive tumor. 
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Introduction 
Glioblastoma (GBM) is the most lethal tumor of 
the central nervous system in adults. Despite recent 
advances in the understanding of the oncogenic 
molecular mechanisms, and improvements in 
neuroimaging technologies, surgery and adjuvant 
treatments, patients with GBM still exhibit a rapid 
unfavorable clinical evolution. The median survival of 
patients is 15 months after diagnosis, a scenario that 
has not changed significantly in the last decades [1-4]. 
In combination with their resistance to most 
 
Ivyspring  
International Publisher 
 Theranostics 2018, Vol. 8, Issue 17 
 
 
http://www.thno.org 
4806 
conventional therapies, including radiotherapy and 
temozolomide (TMZ), GBMs are highly infiltrative 
and diffuse, impeding complete surgical resections. In 
this context, understanding the key underlying 
molecular mechanisms contributing to the 
aggressiveness of this tumor may be a critical step in 
the design of new and more effective precision 
therapies. 
The WNT signaling pathway displays 
pleiotropic physiological functions, ranging from 
neurogenesis to stem cell proliferation, and has been 
implicated in various human cancers, including 
glioma [5-8]. This pathway is particularly relevant in 
the context of cancer stem cells (CSC), which have 
been pointed as critical mediators of cancer recurrence 
and resistance to radio- and chemo-therapy [7, 9-11]. 
Therefore, novel therapeutic strategies targeting 
particular components of the WNT pathway have 
been widely explored [9, 10, 12]. The WNT6 ligand is 
an activator of the WNT pathway, which only recently 
was associated with chemoresistance in gastric and 
bladder cancers [13, 14], poor prognosis of esophageal 
squamous cell carcinoma patients [15], and increased 
risk to develop colorectal adenoma [16]. Importantly, 
no studies to date have explored the relevance of 
WNT6 in human glioma. 
In this work, we show WNT6 is overexpressed in 
GBM, the most common and malignant glioma, and 
displays typical hallmark oncogenic functions in both 
in vitro and in vivo GBM models by affecting the 
activity of classic oncogenic signaling pathways, 
including WNT, SFK and STAT pathways. Critically, 
we provide data from several independent GBM 
patient cohorts establishing WNT6 as a prognostic 
biomarker associated with shorter overall survival.  
Results 
WNT6 is overexpressed in primary GBM 
tissues 
While high WNT6 expression levels were 
previously observed in different human cancer cell 
lines [13, 17, 18], little is known about its specific roles 
in tumors, particularly in GBM. In order to address 
this, we first analyzed gene expression array data 
from normal brains, lower-grade gliomas (LGG, 
WHO grades II and III) and GBM (WHO grade IV) 
patients deposited in TCGA [19]. When compared to 
normal samples, WNT6 was not overexpressed in any 
of the LGG patients (0/27), while 15.6% of GBM 
patients (89/572) presented high WNT6 levels (Figure 
1A; p = 0.026). Concordantly, testing the protein levels 
of WNT6 by immunohistochemistry (IHC) in another 
dataset of glioma tissues (from Hospital Santo 
António; HSA) showed that only GBMs present high 
expression of WNT6 protein (16.3%; Figure 1B 
bottom; p = 0.037). WNT6 immunoreactivity 
expression in glioma showed to be mainly 
cytoplasmic (closed arrowheads), with a diffuse 
pattern where almost all tumor cells are positive 
(Figure 1B, b and c), or a more scattered pattern 
(Figure 1B, d). Tumor-infiltrating lymphocytes were 
negative for WNT6 expression (arrow; Figure 1B, e), 
with endothelial cells being negative or showing some 
faint immunoreactivity (open arrowheads; Figure 1B, 
b, c, d, and f). Representative images of positive and 
negative controls, and hematoxylin and eosin 
stainings are displayed in Figure S1. Together, these 
results show WNT6 mRNA and protein levels 
associate with high glioma grade, suggesting it may 
be important in the pathophysiology of glioma. 
High WNT6 expression is indiscriminately 
present in all molecular subtypes of GBM 
Several efforts have been made to stratify GBM 
into molecular subgroups [20-27]. We evaluated the 
levels of WNT6 expression among the GBM subtypes 
described by Verhaak et al (classical, mesenchymal, 
neural and proneural) [28] in a total of 4 independent 
cohorts, totaling 201 patients from TCGA, 59 from 
Freije, 159 from Gravendeel and 26 from Vital 
datasets. High levels of WNT6 were detected with no 
significant differences in subsets of patients of each 
GBM molecular subtype in all datasets (Figure 1A and 
Figure S2), suggesting WNT6 activation in GBM is 
independent of these molecular signatures. 
WNT6 has oncogenic functions and promotes 
GBM aggressiveness in vitro 
To address whether WNT6 expression influences 
typical cancer hallmark features of GBM cells, WNT6 
expression was silenced in U373MG and SNB19 cell 
lines by shRNA, resulting in significantly decreased 
mRNA and protein levels (Figure 2A-B), as well as 
overexpressed in U87MG cells, which do not express 
WNT6 endogenously (Figure S3A). WNT6-low cells 
presented a significantly lower viability when 
compared with the corresponding WNT6-high coun-
terparts (Figure 2C-D and Figure S3B-C). Concomi-
tantly, WNT6 silencing significantly decreased 
proliferation of GBM cells (Figure 2E). Considering 
GBM cells display remarkable migration and invasion 
potentials, we tested how WNT6 affects these 
hallmark features of GBM. Wound healing migration 
assays and matrigel invasion assays showed that 
WNT6 significantly increases the capacity of GBM 
cells to migrate and invade (Figure 2F-K and Figure 
S3D-E). Together, these data suggest WNT6 is an 
important factor regulating several cancer hallmarks, 
which might influence GBM aggressiveness. 
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WNT6 increases resistance to temozolomide 
chemotherapy in GBM cells 
Previous reports have described the relevance of 
the WNT pathway in increased resistance of many 
cancers to radio- and chemo-therapy [7-9, 15]. In this 
context, we tested whether WNT6 expression may 
have an impact in the sensitivity of GBM cells to 
clinically relevant therapies, including TMZ 
chemotherapy and radiation. Interestingly, 
WNT6-silenced GBM cells were significantly more 
sensitive to TMZ-mediated cell death than their 
respective control cells (Figure 3A-B). In contrast, 
WNT6 did not affect sensitivity of GBM cells to 
radiation treatments (Figure S4). Overall, these results 
suggest WNT6 promotes resistance of GBM cells to 
TMZ, with potential clinical implications as TMZ is 
still the standard-of-care for these patients. 
 
 
Figure 1. WNT6 is overexpressed at the mRNA and protein levels in GBM. (A) Expression levels of WNT6 in 27 lower-grade gliomas (LGG; grey dots), 572 glioblastomas (GBM, 
WHO grade IV; black and colored dots) and 10 unmatched normal brains (black unfilled dots) from TCGA. GBM molecular subtypes are represented as colors (red = classical; blue = 
proneural; green = neural; yellow = mesenchymal). WNT6 is overexpressed (TCGA data level 3 values ≥ 0.41; above red dashed line) in 16% (n = 89) of GBM samples. (B) WNT6 protein 
expression in WHO grades I-IV glioma samples from Hospital Santo António cohort assessed by IHC (n = 63; p = 0.037; chi-squared test). Representative images are shown for a 
WNT6-negative GBM (a), high WNT6 expression in GBM (b) and WHO grade III anaplastic oligoastrocytoma (c), and a WHO grade II diffuse oligodendroglioma with intermediate levels of 
WNT6 expression (d). WNT6 staining was mostly cytoplasmic in glioma cells (closed arrowheads) and not present in lymphocytes (e; arrow), being almost exclusively negative for endothelial 
cells (b-d and f; open arrowheads). Bottom graph summarizes IHC data for the whole dataset. LGG: lower-grade glioma; TCGA: The Cancer Genome Atlas; WHO: World Health 
Organization. 
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Figure 2. WNT6 promotes GBM aggressiveness in vitro. (A-B) The efficiency of WNT6 silencing in U373 and SNB19 glioblastoma cells was analyzed by qRT-PCR and WB (A), and 
immunofluorescence (B). (A) Top: WNT6 expression levels were normalized to TBP. Bottom: WB images are representative of 3 independent assays; α-tubulin was used as reference protein. 
(B) DAPI was used to stain the nucleus (40x magnification; scale bar = 50 µm). (C-D) Cell viability was measured by trypan blue (C) and MTT (D) assays in shCtrl and shWNT6 cells. (E) Cell 
proliferation was evaluated by BrdU incorporation. (F-G) Matrigel invasion assays were used to assess the cells’ invasion capacity. Representative images (F) with cell nuclei stained with DAPI 
(scale bar = 250 µm) and quantification (G) of invasive U373 and SNB19 shCtrl and shWNT6 cells. (H-K) Migration (wound healing) assays were performed in U373 (H-I) and SNB19 (J-K) 
shCtrl and shWNT6 cells to assess the cells’ migration capacity. Representative micrographs throughout time for U373 (H) and SNB19 (J) cells (40x magnification; scale bar = 250 µm). The 
wound gap was measured and expressed as a percentage of wound closure for U373 (I) and SNB19 (K) cells (**** p <0.001; two-way ANOVA post-hoc Sidak’s test). Results represent data 
from at least 3 independent experiments (mean ± SD). *, p < 0.05; **, p < 0.01; ***, p < 0.005 and ****, p < 0.001 (unless otherwise stated, a two-sided unpaired t-test with Welch’s correction 
was applied when homoscedasticity was not verified).  
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Figure 3. WNT6 promotes resistance to temozolomide chemotherapy in GBM cells. (A-B) U373 (A) and SNB19 (B) shCtrl- and shWNT6-transfected cells were treated with 
vehicle or TMZ for 6 days, and cell death was measured by Annexin-V and PI. The graphs present data of 3 independent assays (mean ± SD). Representative dot plots are displayed below. *, 
p < 0.05; **, p < 0.01; ***, p < 0.001 and ****, p < 0.0001 (two-way ANOVA post-hoc Tukey’s test). DMSO: dimethyl sulfoxide; PI: propidium iodide; TMZ: temozolomide. 
 
WNT6 promotes glioblastoma stem cell 
features 
Due to the critical roles of GBM stem cells (GSC) 
in the pathophysiology and clinical outcome of GBM 
patients, we investigated how WNT6 may affect GBM 
cells’ stemness. Interestingly, WNT6-silenced U373 
and SNB19 cells showed prominent decreased levels 
of NESTIN and SOX2 proteins, two common markers 
of GSCs (Figure 4A). In addition, WNT6 expression 
resulted in significantly higher capacities of U373, 
SNB19 and U87 cells to form neurospheres when 
cultured under GSC conditions (Figure 4B-C and 
Figure S3F-G), functionally suggesting WNT6 
contributes to the stem cell phenotype of GBM cells. 
Concordantly, WNT6 expression resulted in 
significantly increased neurosphere-forming 
frequency in a limiting dilution sphere-forming assay 
(1/3.81 for shCtrl vs. 1/16.11 for shWNT6; p = 0.01, 
likelihood ratio test, Figure 4D for U373 cells; SNB19 
cells with WNT6-silencing did not form spheres in the 
tested conditions – data not shown; 1/62.3 for 
U87-Ctrl vs. 1/24.6 for U87-WNT6; p = 0.004, 
likelihood ratio test, Figure S3H), an assay that allows 
the quantification of cells with stem-like properties 
that are capable of forming a new neurosphere 
derived from a single cell. 
In addition to sphere-based stem cell assays, we 
then tested U373 and SNB19 cells cultured under 
specific adherent conditions that allow GSC 
expansion (neurosphere medium supplemented with 
B27, EGF and FGF in laminin-coated wells) [29]. GBM 
cells acquired a more elongated phenotype in these 
adherent stem cell conditions (Figure 4E), as 
previously described [29, 30]. Concordantly with our 
findings in “non-stem cell” conditions (Figure 2C-D), 
WNT6 silencing significantly impaired cell viability of 
U373 and SNB19 GBM cells grown in adherent stem 
cell-like conditions (Figure 4F). Globally, these data 
suggest WNT6 has an important functional role in the 
formation and maintenance of GSCs. 
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Figure 4. WNT6 silencing decreases GBM stem cell features. (A) SOX2 and NESTIN double-immunostaining in U373 (left) and SNB19 (right) shCtrl/shWNT6 cells. DAPI was used 
to stain cell nuclei (40x magnification; scale bar = 50 µm). (B) Representative images of U373 (left) and SNB19 (right) shCtrl/shWNT6 neurospheres at days 10 and 15 after plating, respectively 
(40x magnification; scale bar = 250 µm). (C) Quantification of neurospheres formation (n = 3 independent assays; mean ± SD; *, p < 0.05; **, p < 0.01, two-sided unpaired t-test with Welch’s 
correction being applied when homoscedasticity was not verified). (D) Limiting dilution assays in U373-shCtrl (black) and -shWNT6 (red) cells to assess their sphere-forming capacity. The 
graph is representative of 3 independent assays with similar results. The trend lines represent the estimated active cell frequency (p = 0.01, likelihood ratio test). (E) Representative images 
of U373 (left) and SNB19 (right) shCtrl/shWNT6 cells cultured under stem cell-adherent conditions (scale bar = 250 µm). (F) MTT assay evaluating U373 (left) and SNB19 (right) 
shCtrl/shWNT6 cell viability when cultured under stem cell-adherent conditions (n = 3 independent assays; mean ± SD; **, p < 0.01; ****, p < 0.0001; two-sided unpaired t-test with Welch’s 
correction applied when homoscedasticity was not verified). (G) Heatmap representation of expression levels of WNT6 and 30 stem cell-related genes in 573 GBM patients’ samples from 
TCGA. Each column corresponds to a patient and each line to a gene. Expression values increase from darker blue (low levels) to darker red (high levels). (H) Correlation graphs between 
WNT6 expression (x-axis) and the expression of stem cell genes selected based on the heatmap (y-axis; Pearson’s correlation test; r and p values are indicated). 
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Figure 5. WNT6 accelerates GBM-associated death in an intracranial mouse model. U373 transfected cells were orthotopically injected in the brain of NSG mice (n = 8 per 
group). (A) Weight curves after tumor implantation. (B) Kaplan-Meier overall survival curves of mice (p = 0.0042; Log-rank test). (C-G) Post-mortem brain histological and molecular 
analyses. (C-D) H&E and anti-WNT6 IHC staining were used as controls for GBM formation and successful long-term WNT6 silencing, respectively. (E-G) IHC for cell proliferation/viability 
markers Ki-67 and Cyclin D1 (E), stem cell markers SOX2 and NESTIN (F), and anti-apoptotic marker BCL2 (G). Scale bars’ values are shown in each microphotograph (20 µm or 50 µm). 
H&E: hematoxylin and eosin. 
WNT6 is associated with stem cell-related 
genes in GBM clinical samples 
To further translate our results to the clinical 
setting, we evaluated correlations between the 
expression levels of WNT6 and typical stem 
cell-related genes in GBM patients from TCGA. 
Interestingly, heatmap analyses revealed common 
patterns of gene expression between various stem 
cell-related genes and WNT6 (Figure 4G), and 
individual correlation graphs showed statistically 
significant positive correlations between the 
expression levels of WNT6 and these genes (p < 
0.0001; Figure 4H and Figure S5). These data from 
GBM patients fit well with our in vitro findings, 
further suggesting WNT6 contributes to the stem cell 
phenotype of GBM cells. 
High WNT6 levels accelerate GBM-associated 
death in intracranial mice models 
To expand our findings to in vivo models, 
U373-shCtrl and U373-shWNT6 (Figure 5), or 
U87-Ctrl and U87-WNT6 cells (Figure S3I-L) were 
orthotopically injected in the brain of NSG mice. 
Importantly, all mice bearing WNT6-low tumors 
presented significantly delayed evidences of 
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GBM-related neurological symptoms and slower 
body weight loss than mice bearing WNT6-high 
tumors (Figure 5A and Figure S3I). This was 
accompanied by a significantly longer overall survival 
of U373-shWNT6 and U87-Ctrl mice as compared to 
mice injected with U373-shCtrl and U87-WNT6 cells, 
respectively (Figure 5B and Figure S3J), implicating 
high levels of WNT6 as a negative prognostic 
biomarker in orthotopic GBM in vivo models. 
Post-mortem hematoxylin & eosin (H&E) analyses 
confirmed GBM formation in all animals (Figure 5C 
and Figure S3K), with a very invasive phenotype 
typical of GBM. IHC confirmed long-term WNT6 
silencing and overexpression in U373-shWNT6 and 
U87-WNT6 tumors, respectively (Figure 5D and 
Figure S3L). Histologically, shWNT6 GBM tumors 
also presented: i) lower proliferative activity, as 
observed by decreased Ki-67 and Cyclin D1 
immuno-stainings (Figure 5E); ii) diminished 
expression of the stem cell marker SOX2, despite no 
alteration in the expression of NESTIN (Figure 5F); 
and iii) decreased expression of BCL2 protein, a 
critical anti-apoptotic molecule (Figure 5G). Together, 
these data support WNT6 as a critical mediator of 
GBM aggressiveness in vivo, identifying some 
molecular mediators that might sustain this 
aggressive phenotype, in line with what was observed 
in the in vitro assays. 
WNT6 acts through β-catenin-dependent 
WNT signaling and downstream targets of 
SFKs/STAT pathways 
To explore the underlying molecular 
mechanisms by which WNT6 influences GBM 
aggressiveness, the activation status of a large variety 
of cancer-related kinases was evaluated in U373 and 
SNB19 cell lines using a human phospho-kinase 
antibody array (Figure 6A-B). The phosphorylation 
levels of 4 proteins belonging to the non-receptor 
tyrosine Src family kinases [SFK; namely p-Fgr (Y412), 
p-Yes (Y426), p-Fyn (Y420) and p-Src (Y419)], and 
p-HSP27 (S78/S82), a member of the heat shock 
protein (HSP) family, were significantly decreased 
upon WNT6 silencing in U373 and SNB19 GBM cells 
(Figure 6A-B). In addition, the total levels of β-catenin 
were also decreased upon WNT6 silencing in both cell 
lines (Figure 6A-B).  
Of note, other signaling pathways were 
concordantly affected upon WNT6 silencing in both 
cell lines, but at the level of different proteins. For 
example, the PI3K/AKT/mTOR pathway activation 
was decreased in U373 cells by directly affecting the 
phosphorylation of activating residues of AKT and 
mTOR, two of the major mediators of this pathway. 
While these specific proteins were not significantly 
altered in SNB19 cells, other downstream targets of 
this pathway, such as p70 S6K and eNOS, showed 
decreased phosphorylation levels, globally resulting 
in similar decreased signaling of the PI3K pathway. It 
is also interesting to note that STAT3 phosphorylation 
levels were altered in WNT6-silenced U373 and 
SNB19 cells, but at different residues: serine 727 (S727) 
phosphorylation was increased in U373 cells, while 
tyrosine 705 (Y705) phosphorylation was decreased in 
SNB19 cells (Figure 6A and B). Despite the 
contrasting phosphorylation levels of these STAT3 
residues, the biological meaning is the same, as S727 
phosphorylation inactivates, while Y705 
phosphorylation activates STAT3 activity [31]. 
In addition to these signaling pathways 
concordantly affected in both cell lines, cell-line 
specific effects were also observed, such as alterations 
in the phosphorylation of JNK, GSK-3a/b, and EGFR 
in U373 cells, and of STAT2, STAT5a, STAT5a/b, 
PDGFRb, and c-Jun in SNB19 cells. Again, despite 
these examples of cell-specific effects, the silencing of 
WNT6 consistently resulted in a decreased activation 
status of these cancer-related pathways in GBM. 
To further validate the results obtained in the 
phospho-kinase arrays, the phosphorylation status of 
3 proteins was assessed by western blot (WB) and 
normalized to α-tubulin (reference protein; Figure 
6C-D), as performed in the arrays. Interestingly, WBs 
show a slight decrease of p-STAT3 Y705 in U373 cells, 
and a more prominent decrease in SNB19 cells, as 
evidenced in the phospho-arrays. Similarly, a 
significant decrease of non-p-β-cat S33/S37/T41 
levels upon WNT6 silencing was observed in both cell 
lines, while only U373 presented decreased p-AKT 
S473 phosphorylation levels, further validating the 
phospho-arrays data.  
To confirm that WNT6 activates the canonical 
WNT/β-catenin signaling pathway, TCF/LEF 
reporter assays were performed in both U373 
shCtrl/shWNT6 cells and in U87 Ctrl/WNT6 cells. 
Concordantly to the aforementioned results, GBM 
cells with high levels of WNT6 presented a 
significantly increased activation of the WNT 
canonical pathway as compared to their negative 
counterparts (Figure S6A-D). 
Together, these results suggest that WNT6 acts 
not only through β-catenin-dependent WNT 
signaling, but also through the activation of 
downstream targets of SFKs/STAT pathways, 
highlighting WNT6 as a critical molecule involved in 
a variety of crucial signaling pathways in GBM, which 
associate with the observed oncogenic functional 
effects in vitro and in vivo, and reveal putative novel 
targets for therapeutic interventions in WNT6-high 
GBMs. 
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Figure 6. WNT6 influences the activation status of WNT, SFK, and STAT pathways in GBM. Phospho-kinase arrays were performed to evaluate the phosphorylation status of 
cancer-related kinases in U373 (A) and SNB19 (B). Each array includes 2 technical replicates; 2 and 1 biological replicates were used for U373 and SNB19, respectively. Fold changes between 
phosphorylation levels of proteins in shWNT6 vs. shCtrl cells are shown (mean ± SD). HSP60 was used as reference protein. Similar alterations in the phosphorylation of particular proteins 
for U373 and SNB19 cells are highlighted in red. *, p < 0.05; **, p < 0.01; ***, p < 0.005; ****, p < 0.0001; two-sided unpaired t-test. (C-D) The phosphorylation status of STAT3, β-catenin, 
and AKT, and their respective total forms were assessed in U373 (C) and SNB19 (D) shCtrl and shWNT6 cells by WB (images are representative of 3 independent assays; α-tubulin was used 
as reference protein for normalization; relative expression levels are shown above each band). (E) GSEA analyses identifying signatures of genes significantly associated (ES > 0.3, and FDR < 
0.3) with WNT6 in GBM patients from TCGA. ES: enrichment score; FDR: false discovery rate. 
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WNT6-correlated genes are enriched for 
WNT, AKT, SRC, MYC, JNK and MAPK 
signaling pathways in GBM patients 
To expand the WNT6-associated molecular 
mechanisms detected in vitro (Figure 6A-D) to clinical 
samples of GBM, gene set enrichment analysis 
(GSEA) were performed to identify transcriptomic 
signatures reminiscent of WNT6-associated genes in 
patients (Figure 6E). The gene expression profiles of 
GBM patients from TCGA (n = 573) were gathered, 
and WNT6 expression used as a continuous label (i.e., 
all genes were ranked based on their correlation with 
WNT6). WNT6-positively correlated genes revealed to 
be significantly enriched for genes up-regulated upon 
activation of WNT, AKT, SRC, MYC, JNK and MAPK 
signaling (all enrichment scores, ES > 0.3, and false 
discovery rates, FDR < 0.3; Figure 6E). Concordantly, 
WNT6-negatively correlated genes were enriched for 
genes down-regulated upon WNT signaling 
activation (ES > 0.3 and FDR < 0.3; Figure 6E top left). 
Overall, these transcriptomic results derived from 
GBM samples fit well with our in vitro 
phosphorylation data, where the same pathways were 
shown to be altered upon WNT6 silencing, further 
supporting the critical links between WNT6 and key 
oncogenic signaling pathways associated with glioma 
aggressiveness.  
High levels of WNT6 expression associate with 
shorter overall survival in GBM patients 
Since our data demonstrated critical roles of 
WNT6 in GBM aggressiveness in vitro and in vivo, and 
its association with GBM’s key signaling pathways, 
we investigated the clinical significance of WNT6 
expression in a variety of GBM patient datasets. In our 
Portuguese dataset (Hospital Braga and Hospital 
Santa Maria, n = 51), high levels of WNT6 mRNA 
were significantly associated with shorter overall 
survival (OS) of GBM patients (p = 0.032; log-rank test; 
Figure 7A). Importantly, this association between 
high WNT6 mRNA levels and poor prognosis in GBM 
patients was further validated in 3 additional 
independent datasets: Freije (n = 59) [24], Gravendeel 
(n = 159) [32] and Vital (n = 26) [33] datasets (p = 0.006, 
p = 0.029, p = 0.02, respectively; Figure 7B-D). These 
findings were then validated in 407 GBM patients 
with available survival data from TCGA (Table 1), in 
which a multivariable Cox model showed a 
statistically significant association between higher 
values of WNT6 expression and shorter OS of GBM 
patients (p = 0.030), independently of other prognostic 
variables, including patient age (p < 0.0001), 
Karnofsky performance status (KPS; p = 0.001), gender 
(p = 0.037) and treatment with chemo- or 
radio-therapy (p < 0.0001; Table 1). Moreover, high 
levels of WNT6 protein expression, evaluated by IHC 
in a GBM Brazilian cohort (n = 87), also showed an 
evident trend for shorter OS (p = 0.069; Figure S7), 
highlighting that both mRNA and protein levels of 
WNT6 may be used as a clinically valuable biomarker. 
To reinforce this association, a meta-analysis 
including all independent datasets showed that 
WNT6-high expression is globally associated with 
shorter survival of GBM patients (Hazard Ratio = 
1.637; 95% confidence interval: 1.285 – 2.086; p < 
0.0001; Figure 7E). Together, these results suggest that 
WNT6 expression may be a new prognostic factor 
useful for the stratification of GBM patients. 
 
Table 1. High levels of WNT6 expression are significantly 
associated with shorter survival of GBM patients (n = 407; 
microarray data). 
  Overall survival 
  p-value Exp(B) 
WNT6 expression 0.03 1.288 
Age <0.0001 1.029 
KPS 0.001 0.984 
Gendera,b 0.037 0.771 
Chemo- or Radiotherapya,c <0.001 0.192 
aGender and Chemo- or Radiotherapy was used as categorical variables; 
bFemale (n = 154) vs Male (n = 253); 
cTreatment (n = 383) vs No treatment (n = 24). 
 
Discussion 
Deregulated signaling of the WNT pathway has 
been reported in several human cancers, including 
GBM, and has been associated with treatment 
resistance [13, 34-36]. This is partly due to stem cell 
features sustained by WNT signaling, such as 
increased proliferation and migration [34]. The 
present study is the first dissecting the functional 
roles and underlying molecular mechanisms 
mediated by WNT6 activation in human GBM, 
establishing it as a clinically relevant prognostic 
biomarker (Figure 7, Figure 8, Table 1, and Figure 
S7). Due to its critical functions during embryogenesis 
[37-42], deregulated expression of WNT6 in adults 
may favor tumorigenesis [13-16]. Our data show that 
the expression of WNT6 in gliomas is 
grade-dependent, at the gene and protein levels 
(Figure 1), similarly to what was previously described 
for other WNT ligands [5, 6, 43-46], thus associating 
WNT6 with increased malignancy of gliomas. In 
addition, our findings demonstrate prominent effects 
of WNT6 on GBM cell viability, proliferation, glioma 
stem cell capacity, invasion, migration and sensitivity 
to TMZ-based chemotherapy, comprehensively 
implicating WNT6 as an important oncogenic factor 
in glioma (Figure 2, Figure 3, Figure 4, and Figure 
S3). This is in agreement with the known effects of 
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other WNT ligands in GBM [5, 6, 44, 46, 47]. 
According to the definition of CSC [48], we showed 
that WNT6 expression not only correlates with the 
expression of cancer stem cell-associated genes, but 
also functionally impacts the self-renewal capacity of 
GSC (Figure 4 and Figure S3F-H). Concordant with 
the functional effects, molecular data also showed 
WNT6 associates with typical GSC markers, both in 
GBM cells and patient samples.  
 
 
Figure 7. WNT6 expression is prognostically valuable in GBM patients. Kaplan-Meier survival curves of WNT6-low and WNT6-high GBM patients derived from qRT-PCR data (A) 
or microarray (B-E) data. (A) Portuguese dataset, n = 51, median OS 16.9 vs. 10.4 months (low vs. high WNT6 expression, respectively; p = 0.032, Log-rank test). (B) Freije dataset, n = 59, 
median OS 9.6 vs. 5 months (p = 0.006, Log-rank test). (C) Gravendeel dataset, n = 159, median OS 10.1 vs. 6 months (p = 0.029, Log-rank test). (D) Vital dataset, n = 26, median OS 18 vs. 
4 months (p = 0.02, Log-rank test). (E) Forest plot of hazard ratios (HR), illustrating the associations between WNT6 expression and overall survival in GBM patients. Each cohort is 
accompanied by its HR (black square; the size of the square represents the weight of the study in the meta-analysis) and 95% confidence intervals (extending lines). The diamond represents 
the estimated pooled effect (HR = 1.637; 95% confidence interval: 1.285 – 2.086; p < 0.0001). CI: confidence interval; HR: hazard ratio. 
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Figure 8. Proposed model for the functional, molecular and clinical impact of WNT6 in GBM. WNT6-high GBM cells present increased proliferation, invasion, migration, TMZ 
resistance and stem cell self-renewal capacities, which are accompanied by activation of the WNT, SFK, RTK, STAT and AKT pathways. Clinically, WNT6-high tumors cause shorter overall 
survival (both in mouse GBM models and human patients). 
 
Considering the global effects of WNT6 in GSC 
phenotypes (Figure 4 and Figure S3F-H), cell motility 
capacity (Figure 2 and Figure S3D-E), and resistance 
to chemotherapy (Figure 3), it will be interesting to 
evaluate its potential value as a biomarker for tumor 
recurrence, which is of paramount importance to the 
clinical management of GBM as these patients recur 
almost universally after treatment. Importantly, we 
also demonstrated that WNT6 is a novel biomarker of 
GBM prognosis, as patients with WNT6-high tumors 
from a variety of independent datasets presented a 
significantly shorter OS than WNT6-low tumors 
(Figure 7, Table 1, and Figure S7), a clinical finding 
that is in agreement with our in vivo data (Figure 5 
and Figure S3I-J). This might be linked to the WNT6 
oncogenic activities, such as increased invasion/ 
migration hampering complete tumor resection, 
increased tumor relapse probability due to its roles in 
GSC maintenance (Figure 4 and Figure S3F-H), and 
the response to TMZ treatment (Figure 3), which is 
still the gold-standard chemotherapeutic drug used 
for GBM patients. These findings fit well with 
previous reports describing that WNT6 increases the 
chemo-resistance of gastric [13] and bladder [14] 
cancer, and associates with the overall and 
disease-free survivals of esophageal squamous cell 
carcinoma patients [15]. Together, these data 
implicate WNT6 as a novel prognostic biomarker and 
putative therapeutic target for GBM patients. The fact 
that WNT6 levels can be easily assessed at the mRNA 
or protein levels with routine molecular biology 
techniques may also facilitate the widespread imple-
mentation of this biomarker in the clinical settings. 
Taking into consideration that (i) the first step for 
designing novel therapeutic strategies requires not 
only the identification of new molecular targets, but 
also the understanding of their functional 
mechanisms, and (ii) nothing was known of 
WNT6-mediated signaling mechanisms in GBM or 
any other cancer type, our phospho-kinase arrays 
provide the first data on the activation status of 
several cancer-related pathways that may be 
regulated by WNT6 (Figure 6). The effects observed in 
β-catenin in U373 and SNB19 cells clearly suggest that 
WNT6 might act through the canonical WNT 
pathway in GBM, which was further validated with 
the TCF/LEF reporter assays in U373 and U87 cells 
(Figure S6). In addition, WNT6 silencing led to 
reduced phosphorylation/activation states of 4 
non-receptor tyrosine Src kinases (Fgr, Yes, Fyn and 
Src), which have been described to contribute to the 
activation of downstream targets of RTKs, such as 
EGFR, influencing glioma aggressiveness [49-51]. 
WNT6 silencing also resulted in decreased 
phosphorylation of HSP27, an anti-apoptotic protein 
[52] associated with increased cell proliferation and 
decreased Fas-induced apoptosis in prostate cancer 
[53], and was shown to mediate the activation of 
p38/ERK (MAPK) pro-survival signaling in cervical 
cancer cells [54]. Nevertheless, other cell line-specific 
alterations in WNT6-silenced cells, namely in p-AKT, 
p-TOR and p-PRAS40 in U373 cells, clearly 
demonstrate the association between WNT6 and the 
activation of the PI3K/AKT/mTOR pathway, which 
is known to have a major role in the oncogenic process 
of GBM cells [55]. Regarding p-STAT3 alterations 
upon WNT6 silencing, it was reported that reduced 
p-STAT3 S727 or increased p-STAT3 Y705 lead to 
more aggressive glioma tumors in vivo, and enhanced 
glioma proliferation and invasion in vitro [31], which 
also fits well with a WNT6-mediated oncogenic role in 
GBM. Importantly, GSEA data derived from clinical 
GBM samples further supported the molecular links 
between WNT6 and these cancer-related pathways. In 
this context, our results, together with the reports 
associating the WNT pathway with the MAPK, PI3K 
and STAT3 pathways [56-63], strongly support a role 
of WNT6 in the regulation of these cancer-related 
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pathways and suggest that WNT6 acts, at least partly, 
through the canonical WNT signaling, independently 
of the expression of other well-known canonical WNT 
ligands (WNT1 and WNT3a; Figure S8). Future work 
should focus on the potential predictive value of 
WNT6 for targeted therapies with specific inhibitors 
of WNT-related pathways (e.g., LGK974, currently 
tested in clinical trials for several solid tumors; 
NCT01351103).  
In summary, this work provides significant 
contributions to the neuro-oncology field, profiting 
from the understanding of WNT6-mediated signaling 
pathways and from the portrayal of the functional 
roles and clinical value of WNT6 in GBM, potentially 
impacting prognostic stratification and aiding in 
rational treatment decisions for GBM patients.  
Methods 
TCGA data analysis in glioma patients 
All gene expression data from samples 
hybridized by the University of North Carolina, 
Lineberger Comprehensive Cancer Center, using 
Agilent G4502A 244K, were downloaded from TCGA 
(https://portal.gdc.cancer.gov/) [19], including 572 
GBMs, 27 LGGs, and 10 unmatched non-tumoral 
patient samples. To prevent duplicated entries from 
the same patient—when more than one portion per 
patient was available—the median expression value 
was used. Three probe sets hit WNT6 gene 
(A_23_P119916, A_32_P159877 and A_24_P208513). 
The provided value was pre-processed and 
normalized according to “level 3” specifications of 
TCGA. WNT6 overexpression in glioma samples was 
considered when higher than that in non-tumoral 
samples (“level 3” value ≥ 0.41). Clinical data of each 
patient was provided by the biospecimen core 
resources and includes information about patients’ 
age at diagnosis, gender, KPS and days to death and 
to last follow-up. 
Freije, Gravendeel and Vital datasets 
WNT6 expression microarray data from Freije (n 
= 59) [24], (Gravendeel) n = 159 [32], and Vital (n = 26) 
[33] datasets of GBM patients were obtained in the 
GlioVis data portal [64]. The top 17% of tumors 
expressing highest levels of WNT6 were classified as 
WNT6-high in Freije (n = 10/59) and Gravendeel (n = 
27/159) datasets, similar to the cutoff used for TCGA, 
and the top 39% for the Vital (n = 10/26) dataset due 
to the small number of patients. Clinical data included 
GBM subtype classification, OS and vital status of the 
patients.  
Glioma primary tissues 
Glioma tumor specimens were obtained from 
patients who underwent a craniotomy for tumor 
removal or stereotaxic biopsy at 4 different hospitals: 
Hospital Braga (HB), Hospital Santa Maria (HSM, 
Centro Hospitalar Lisboa Norte; samples requested 
from Biobanco-iMM, Lisbon Academic Medical 
Center, Lisbon, Portugal) and Hospital Santo António 
(HSA, Centro Hospitalar Porto), Portugal, and 
Hospital de Câncer de Barretos, Brazil. Samples from 
HB and HSM were reserved for RNA-based studies, 
transported in dry ice to the lab and stored at -80 °C. 
Samples from HSA and Brazil were formalin-fixed 
and paraffin-embedded and used for IHC analysis. 
Samples from Brazil were organized in triplicates into 
tissue microarrays (TMAs) [65]. Tumors were 
classified according to WHO 2007 [66] and only 
patients with glial tumor histological diagnosis were 
included in the study.  
Immunohistochemistry 
Tissues sections were deparaffinized and 
rehydrated by xylene and ethanol series. Sodium 
citrate buffer (10 mM, 0.05% Tween 20, pH 6) was 
used for antigen retrieval. Endogenous peroxidase 
activity was blocked with 3% H2O2 in TBS 1x for 10 
min. Immunohistochemical staining was performed 
using the LabVision kit (UltraVision Large Volume 
Detection System Anti-polyvalent, HRP) according to 
the manufacturer’s instructions. WNT6, Ki-67, Cyclin 
D1, SOX2, Nestin, GFAP and BCL2 antibodies were 
used (see Table S1 for details). Concerning Ki-67 
staining, before antigen retrieval, tissues were 
permeabilized using TBS-Tween 0.5%, for 10 min. 
DAB substrate (DAKO) was used as chromogen, 
followed by counterstaining with hematoxylin. The 
TMA from the Brazilian cohort was blind-scored by a 
pathologist based on WNT6 staining intensity: 1 = 
weak, 2 = moderate and 3 = strong. The average of the 
triplicate spots was calculated and used for the 
survival analysis. An average > 2 was considered as 
WNT6 high expression. 
Cell lines and culture conditions 
Human GBM cell lines U373MG and U87MG 
(kindly provided by Dr. Joseph Costello, University of 
California, San Francisco), and SNB19 (obtained from 
German Collection of Microorganisms and Cell 
Cultures) were cultured in DMEM (Biochrom) 
supplemented with 10% Fetal Bovine Serum (FBS; 
Biochrom). Cells were maintained in a humidified 
atmosphere at 37 °C and 5% (v/v) CO2. These 
conditions were maintained throughout the studies, 
unless otherwise stated. Testing for mycoplasma 
contamination was performed every month.  
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WNT6-silencing by shRNA in GBM cells 
U373MG and SNB19 cell lines were plated at 
70 000 cell/well (24-well plate) and 100 000 cells/well 
(12-well plate), respectively. Cells were transfected 
with WNT6 gene-specific shRNA expression vector 
inserted in a pRS plasmid (TR308360, clones TI333434 
and TI333435 from Origene; named U373-shWNT6 or 
SNB19-shWNT6, respectively) or with a scrambled 
negative control non-effective shRNA in a pRS 
plasmid (TR30012, Origene; named U373-shCtrl or 
SNB19-shCtrl). Lipofectamine 3000 (Invitrogen) 
transfection reagent was used according to the 
manufacturer’s recommendations (ratio plasmid/ 
lipofectamine, 1:2.5). Stable transfection was achieved 
by selecting transfected clones with puromycin (1 
µg/mL).  
WNT6 overexpression in GBM cells 
U87MG cells were plated at 200 000 cell/well 
(6-well plate). Cells were transfected with the 
pcDNA-Wnt6 vector (gift from Dr. Marian Waterman; 
Addgene plasmid #35913) [67] or with the respective 
empty vector (pcDNA3.2 GW delCMV; gift from Dr. 
Edward Hsiao; Addgene plasmid #29496) [68]. 
Lipofectamine 3000 (Invitrogen) transfection reagent 
was used according to the manufacturer’s 
recommendations (4 µL of Lipofectamine 3000 per 1 
µg of DNA). Stable transfection was achieved by 
selecting transfected clones with geneticin (800 
µg/mL).  
qRT-PCR 
Total RNA was extracted from GBM patients’ 
tissues and cell lines using the TRIzol method 
(Invitrogen) and cDNA from 1 µg of the total RNA 
was then synthesized (RT-Phusion Kit, Thermo 
Scientific). The levels of WNT6 and TBP (reference 
gene) were assessed by quantitative reverse 
transcription-PCR (qRT-PCR; KAPA SYBR® FAST 
qPCR Kit, KAPA BIOSYSTEMS or PowerUp™ 
SYBR™ Green Master Mix, ThermoFisher Scientific, 
for cell lines and GBM patient’s samples, respectively) 
with the following sets of primers: WNT6 Fwd 
5’–GACGAGAAGTCGAGGCTCTTT–3’ and Rev 
5’–CGAAATGGAGGCAGCTTCT–3’; TBP Fwd 
5’–GAGCTGTGATGTGAAGTTTCC–3’ and Rev 
5’–TCTGGGTTTGATCATTCTGTAG–3’. The 
annealing temperature was 60 °C for both. The levels 
of WNT1 and WNT3a were assessed using Taqman 
gene expression assays (Hs00180529_m1 and 
Hs00263977_m1, respectively) and normalized 
against TBP (Hs00427620_m1), following the 
manufacturer’s instructions. Levels were determined 
based on the 2-∆∆Ct method, as previously described 
[69]. 
Immunofluorescence (IF) 
U373 (shCtrl/shWNT6) and SNB19 
(shCtrl/shWNT6) cells were plated on coverslips in 
DMEM supplemented with 10% FBS. Cells were fixed 
with paraformaldehyde 4% and then incubated in 1% 
BSA in PBS/0.1% Tween for 1 h. Afterwards, cells 
were incubated overnight at 4 °C with the primary 
antibody against WNT6 or SOX2. Alexa fluor® 594 
goat anti-rabbit IgG (H+L; A-11012, ThermoFisher 
Scientific) secondary antibody was used. 
Additionally, SOX2-coverslips were incubated with 
anti-NESTIN primary antibody. Next, Alexa Fluor® 
488 goat anti-mouse IgG (H+L; A-11001, 
ThermoFisher Scientific) secondary antibody was 
used. DAPI (VECTASHIELD® Mounting Medium 
with DAPI, Vector Laboratories) was used to stain the 
cell nucleus (blue) at a concentration of 1.5 µg/mL. 
Further details about the antibodies used are 
provided in Table S1. 
Cell viability assays 
Cell viability was determined 6 days after 
plating by both trypan blue and MTT (U373 and 
SNB19 cells) or MTS (U87 cells) assays. For trypan 
blue assay, cells were plated, in triplicate, at an initial 
density of 20 000 cells/well in 6-well plates. For 
MTT/MTS assay, transfected cells were plated in 
12-well plates, in triplicate, at an initial density of 
6 000 (for U373 and U87 cells) or 10 000 cells/well 
(SNB19).  
For the MTT assay, cells were incubated with 0.5 
mg of MTT (ThermoFisher Scientific) per mL of PBS 
1x, for up to 2 h in a humidified atmosphere at 37 °C 
and 5% CO2. Subsequently, the formed crystals were 
dissolved using an acidified isopropanol solution 
(0.04 M HCl in isopropanol), as described in [70], and 
the absorbance was read at 570 nm. For the MTS 
assay, cells were incubated with 10% of the MTS 
solution (CellTiter 96® AQueous One Solution Cell 
Proliferation Assay; Promega) in DMEM 
supplemented with 10% FBS, for up to 1 h in a 
humidified atmosphere at 37 °C and 5% CO2. 
Absorbance was recorded at 490 nm. 
Cell proliferation 
Cell proliferation was evaluated based on the 
measurement of BrdU incorporation during DNA 
synthesis (Cell Proliferation ELISA, BrdU colorimetric 
assay, Roche), as recommended by the manufacturer. 
Briefly, cells were cultured in DMEM (Gibco®) 
supplemented with 10% FBS (Biochrom) in 96-well 
plates (cell density: 2 000 cells/well) for 4 days. After 
that, BrdU was added to the cells and they were 
re-incubated for 4 h. 
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Cell migration 
Ibidi 2-well inserts (Ibidi) with a cell-free gap 
were used in 12-well plates to evaluate cell migration 
by wound healing assay. U373 and SNB19 transfected 
cells were plated in triplicate, at an initial density of 
70 000 and 60 000 cells in each side of the insert, 
respectively, and left to adhere overnight. After that, 
inserts were removed (0 h time-point) and wells were 
washed with PBS to remove dead cells and debris. 
The migration of the cells into the gap was imaged (2 
images/well) over hours until wound closure was 
achieved (images were captured at the same locations 
over time). The gap size (pixels) was measured using 
an automated software (beWound – Cell Migration 
Tool, v1.7, BESURG, Portugal; www.besurg.com) and 
manually verified and corrected when deemed 
necessary. At least 15 lines equally spaced across the 
image and perpendicular to the gap main axis were 
used for increased measurement representativeness.  
Cell invasion 
Cell invasion was assessed using the BD 
BioCoat™ Matrigel™ Invasion Chambers (Corning®) 
as recommended by the manufacturer. Briefly, cells 
were seeded into the top (insert) at the initial density 
of 50 000 cells/well (U373 and SNB19) or 25 000 
cells/well (U87; 24-well chambers) in DMEM 
(Gibco®) supplemented with 1% FBS. EGF was added 
to the medium of the lower chamber (DMEM 
supplemented with 10% FBS) at a concentration of 20 
ng/mL, as chemoattractant. Cells were incubated for 
22 h. Next, cells that invaded through the membrane 
were stained using VECTASHIELD Mounting 
Medium with DAPI (Vector Laboratories) and a 
picture of the entire membrane was obtained using an 
Olympus Upright BX61 microscope. The total cell 
number was counted with the help of ImageJ software 
(version 1.49). 
Cell death 
Cell death was evaluated after 6 days of 
treatment with TMZ (400 µM and 800 µM, for U373 
and SNB19 transfected cells, respectively) or DMSO 
(Dimethyl sulfoxide; Vehicle). TMZ treatment was 
applied 24 h after plating and was renewed 2 days 
after. Cells were stained with Annexin V-FITC (BD 
Bioscience) and propidium iodide (PI; TermoFisher 
Scientific), according to the manufacturer’s protocol, 
followed by flow cytometry analysis. At least 10 000 
events were acquired. Results were analyzed using 
FlowJo software (version 10).  
Colony formation assay 
For clonogenic cell survival assay, cells were 
seeded at a density of 1 000 to 2 000 per 25-cm2 flask, 
in triplicates. Twenty-four hours after seeding, 
irradiation was performed at RT in single exposure 
doses, delivered by a Novalis TX® linear accelerator, 
with a nominal energy of 6 MV at a dose rate of about 
400 cGy/min. Doses of 2 and 4 Gy were calculated 
using a dedicated treatment planning system to a 
depth of water of 1.5 cm. The plating efficiency (PE) 
represents the percentage of seeded cells that grew 
into colonies. Colonies with more than 50 cells were 
counted by microscopic inspection and PE, as well as 
the radiation-surviving fraction (PE of experimental 
group/PE of control group), were determined. 
Survival data were obtained with data from 3 
independent experiments. 
Cell viability assay (MTT) under stem cell 
conditions 
Culture vessels were coated with 10 µg/mL 
natural mouse laminin (Invitrogen) for 3 h at 37 °C or 
overnight at 4 °C, as previously described [29]. U373 
and SNB19 transfected cells were plated in 12-well 
laminin-coated plates, in triplicate, at an initial 
density of 6 000 and 10 000 cells per well, respectively. 
Cells were cultured in serum-free stem cell medium 
composed by DMEM-F12 (Gibco) supplemented with 
1x B27 (Invitrogen), 20 ng/mL of EGF (Invitrogen), 
and 20 ng/mL of basic fibroblast growth factor 
(b-FGF, Invitrogen). After 4 days in culture, cells were 
incubated with MTT as detailed above (section “Cell 
viability assays”). 
Neurosphere formation assay 
U373, SNB19 and U87 transfected cells were 
plated at the maximum density of 4 000 cells/mL in 
low-attachment 24-well plates (Corning). Cells were 
cultured in serum-free stem cell medium, as detailed 
above. Neurospheres were supplemented with fresh 
media every 4–5 days (250 µL/well). The number of 
neurospheres was counted after 10 days for U373 and 
U87 cells and 15 days for SNB19. 
Limiting dilution assay 
Cell numbers of U373 and U87 transfected cells 
were adjusted to a starting concentration of 40 000 
cells/mL and 160 000 cells/mL, respectively, from 
which multiple serial dilutions were performed and 
plated in low-attachment 96-well plates (Corning). At 
the end, cell densities ranged from 1 000 to 1 cells per 
well in a final volume of 100 µL for U373 cells and 
from 4 000 to 8 cells per well for U87 cells. Cells were 
cultured in serum-free stem cell medium, as detailed 
above. Cultures were disturbed only for media 
supplementation every 5 days. After 15 days, the 
fraction of wells not containing neurospheres was 
determined for each condition and plotted against the 
initial plated cell density. Stem cell frequencies and 
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statistical significance were calculated using the 
Extreme Limiting Dilution Assay (ELDA) software 
available at http://bioinf.wehi.edu.au/software/ 
elda/ [71]. 
Stereotactic orthotopic xenografts 
NSG (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) mice aged 
4 months were anesthetized with a mixture of 
ketamine (75 mg/kg) and medetomidine (1 mg/kg) 
supplemented with butorphanol (5 mg/kg) for its 
analgesic properties and placed into the digital 3-axis 
stereotaxic apparatus (Stoelting). A total of 5×105 
U373 or 2×105 U87 transfected cells (resuspended in 5 
µL PBS 1x) were injected into the brain striatum using 
a 10 µL Hamilton syringe with a point style 4 beveled 
26s-gauge needle, as previously described [72]. A total 
of 8 male and 6 female mice per group were used for 
U373 and U87 transfected cells, respectively. U373 
and U87 cells were used as no reports were found for 
SNB19 tumorigenic capacity when orthotopically 
injected in immunocompromised mice. Mice were 
maintained under standard laboratory conditions, 
which included an artificial 12 h light/dark cycle, 
controlled ambient temperature (21 ± 1 °C) and a 
relative humidity of 50–60%. The confirmation of 
specified pathogen-free health status of sentinel mice 
maintained within the same animal room was 
performed according to FELASA guidelines. 
Experimental mice were always manipulated in a 
flow hood chamber, except during the surgery. Mice’s 
body weight was evaluated 3 times per week, while 
general behavior and symptomatology were 
registered daily. Sacrifice at the pre-established 
humane endpoint was performed when mice 
presented severe weight loss (> 30% from maximum 
weight). Death was used for Kaplan-Meyer 
representation. 
Human phospho-kinase antibody array 
Human phospho-kinase antibody arrays 
(ARY003B; R&D systems) were used to 
simultaneously detect the relative levels of 
phosphorylation of 43 kinase phosphorylation sites 
and 2 related total proteins. Capture and control 
antibodies were spotted in duplicate on nitrocellulose 
membranes. The protocol was done following the 
manufacturer’s recommendations. In this case, 400 µg 
of total protein from all cell lines (U373 
shCtrl/shWNT6 and SNB19 shCtrl/shWNT6) was 
used. The obtained chemiluminescence was measured 
using the ChemiDoc imaging system (Biorad). 
Adjusted volume per spot (i.e., average pixel intensity 
of the spot times its area, corrected for the 
background) was measured using the Quantity One 
image analysis software. Background was eliminated 
using the local option. The average of each duplicated 
spot was calculated, normalized to HSP60 (reference 
protein) and used to determine the relative change in 
phosphorylated kinase proteins between shCtrl and 
shWNT6 conditions. Two sets of arrays were 
performed for U373 shCtrl/shWNT6, while only 1 
was used for SNB19 shCtrl/shWNT6. 
Western blot analysis 
Cells were washed with PBS 1x and removed by 
scratch in a lysis buffer containing 50 mM Tris pH 8, 2 
mM EDTA pH 7.4, 0.1% SDS, 1% NP-40 and 150 mM 
NaCl, inhibitors of proteases 1x (B14001, Biotool) and 
phosphatases 1x (B15001, Biotool). After a 15 -min 
incubation on ice, whole cell lysate was centrifuged at 
13 000 × g for 15 min at 4 °C. The total protein 
concentration was determined from the obtained 
supernatant using the PierceTM BCA protein assay kit 
(ThermoFisher Scientific), according to the 
manufacturer’s protocol. Protein extracts (denatured 
and reduced; 20 µg/lane) were separated in a 10% 
SDS-polyacrylamide gel by electrophoresis and 
transferred to nitrocellulose membranes (Hybond-C 
Extra, GE Healthcare Life Sciences), using the 
Trans-blot turbo transferring system (Bio-rad), 
following the manufacturer’s instructions. A protein 
ladder (Page ruler prestained protein ladder; 
Fermentas) was used to determine the approximate 
protein size and to monitor the progress of the 
electrophoretic run and the success of the transfer. 
Before starting the immunodetection, membranes 
were blocked with BSA (5% in TBS 1x), for 1 h at RT. 
The immunodetection was achieved using antibodies 
against p-STAT3 Y705, STAT3, non-p-β-catenin 
S33/S37/T41, β-catenin, p-AKT S473, AKT, and 
α-tubulin (see Table S1 for details). Blots were 
revealed with peroxidase-conjugated secondary 
anti-mouse and anti-rabbit IgG antibodies (see Table 
S1 for details), followed by enhanced 
chemiluminescence (ECL) solution (SuperSignal West 
Femto Chemiluminescent Substrate; Thermo 
Scientific). The obtained chemiluminescence was 
measured using the ChemiDoc imaging system 
(Biorad). If necessary, membranes were stripped 
using the Restore™ PLUS Western Blot Stripping 
Buffer (Thermo Fisher Scientific), following the 
manufacturer’s recommendations. As for the 
phospho-kinase arrays, adjusted volume per band 
was measured using the Quantity One image analysis 
software. Phosphorylated protein values were 
normalized to α-tubulin (reference protein). 
TCF/LEF reporter assay 
The Cignal TCF/LEF Reporter Assay Kit (GFP; 
Qiagen) was used to quantify the specific activation of 
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β-catenin-dependent WNT signaling (canonical 
pathway). The protocol was done following the 
manufacturer’s recommendations. Briefly, 
U373-shCtrl, U373-shWNT6, U87-Ctrl and U87-WNT6 
cells were reverse transfected with i) a TCF/LEF 
reporter vector, which encodes a monster GFP under 
the control of a TATA box (basal promoter) joined to 
TCF/LEF responsive elements; ii) a negative control 
vector, which encodes GFP under the control of a 
TATA box; or iii) a positive control vector, which 
constitutively expresses the monster GFP for visual 
confirmation of the transfection efficiency. For this, 
cells were plated in triplicate at an initial density of 
20 000 cells/well in 96-well plates with black walls 
and clear bottoms (Glass SPL Black plate). 
Lipofectamine 3000 (Invitrogen) transfection reagent 
was used according to the manufacturer’s 
recommendations (0.25 µL of Lipofectamine 3000 per 
100 ng of DNA). After 16 h of transfection, the 
medium was renewed and 24 h post-transfection, cells 
were treated with 50 mM of LiCl. GFP expression was 
verified 24 h after treatment under the microscope 
and quantified using a Varioskan Flash (Thermo 
Fisher Scientific) plate reader (excitation at 488 nm 
and emission at 515 nm). GFP expression in the 
reporter assay condition was normalized against the 
negative controls (as blank) and the respective 
positive controls (to control for transfection 
efficiency). 
Gene Set Enrichment Analysis (GSEA) 
The raw expression data profile (Agilent G4502A 
244K) of all GBM patients from TCGA (n = 573) was 
extracted as detailed above. GSEA 
(www.broad.mit.edu/gsea/) software was then used 
[73]. In this work, a continuous phenotype profile was 
employed to find gene sets that correlate with WNT6 
(gene neighbors). Accordingly, Pearson’s correlation 
was used to score and rank the genes. Gene sets from 
the Molecular Signature Database (MSigDb) C6 
collection were used. Default options were used, 
unless otherwise stated. Significant enrichments were 
considered when false discovery rate (FDR) < 0.30. 
Statistical analyses 
Homoscedasticity was verified with Levene’s 
test and differences between groups were assessed by 
a two-sided unpaired t-test, with Welch’s correction 
applied accordingly. For the wound healing assay and 
radiation treatment sensitivity assay, a two-way 
ANOVA followed by the post-hoc Sidak’s test for 
multiple comparison testing was used. For the TMZ 
treatment cell death assay, a two-way ANOVA 
followed by the post-hoc Tukey’s test for multiple 
comparison testing was used. The correlation between 
the expressions of WNT6 and stem-related genes 
(from the gene ontology gene-set GO_Positive_ 
regulation_of_stem_cell_proliferation) was calculated 
using Pearson’s correlation coefficient (r). The effects 
of WNT6 on mouse OS was assessed by log-rank test. 
These analyses were performed with GraphPad Prism 
6.01 software (GraphPad software, Inc.). 
The Chi-square test was used to assess the 
difference between the distributions of tumors with 
high and low WNT6 expression stratified for LGGs 
and GBMs. To evaluate the prognostic value of WNT6 
expression, univariate or multivariate analyses of 
survival were performed using, respectively, the 
log-rank test or the Cox proportional hazard model, 
where the potential confounding effect of some 
variables is considered. These analyses were made 
with SPSS 22.0 software (SPSS, Inc.). A meta-analysis 
including all datasets was performed with the 
Comprehensive Meta Analysis (CMA) v3 software 
(Biostat, Inc.). Hazard ratios and 95% confidence 
intervals from the Cox univariate or, when possible, 
multivariate analyses were used. A random effects 
statistical model was applied. 
For all statistical tests, significance was 
considered when p < 0.05.  
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